First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with
6 hours ago
- #clinical trial
- #immunotherapy
- #esophageal squamous cell carcinoma
- Tislelizumab plus chemotherapy showed improved median overall survival (24.5 vs. 15.1 months) compared to placebo plus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma.
- Progression-free survival and objective response rate were higher with tislelizumab plus chemotherapy, with an ORR of 63.6% versus 45.5% in the placebo arm.
- Treatment-related adverse events were more common with tislelizumab plus chemotherapy, but no TRAE-related deaths occurred, indicating a tolerable safety profile.